215 related articles for article (PubMed ID: 27551051)
1. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study.
Nestoriuc Y; von Blanckenburg P; Schuricht F; Barsky AJ; Hadji P; Albert US; Rief W
Ann Oncol; 2016 Oct; 27(10):1909-15. PubMed ID: 27551051
[TBL] [Abstract][Full Text] [Related]
2. What do women with breast cancer expect from their treatment? Correlates of negative treatment expectations about endocrine therapy.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Rief W; Witzel I; Albert US; Nestoriuc Y
Psychooncology; 2016 Dec; 25(12):1485-1492. PubMed ID: 26913587
[TBL] [Abstract][Full Text] [Related]
3. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial.
von Blanckenburg P; Schuricht F; Albert US; Rief W; Nestoriuc Y
BMC Cancer; 2013 Sep; 13():426. PubMed ID: 24047450
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
5. Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.
Pan Y; Heisig SR; von Blanckenburg P; Albert US; Hadji P; Rief W; Nestoriuc Y
Breast Cancer Res Treat; 2018 Apr; 168(3):667-677. PubMed ID: 29330625
[TBL] [Abstract][Full Text] [Related]
6. Managing side effects in adjuvant endocrine therapy for breast cancer.
Condorelli R; Vaz-Luis I
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1101-1112. PubMed ID: 30188738
[TBL] [Abstract][Full Text] [Related]
7. Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.
Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
Oncologist; 2015 Jun; 20(6):598-604. PubMed ID: 25933930
[TBL] [Abstract][Full Text] [Related]
8. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
[TBL] [Abstract][Full Text] [Related]
9. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
10. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
[TBL] [Abstract][Full Text] [Related]
11. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
12. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study.
DeCensi A; Bonanni B; Maisonneuve P; Serrano D; Omodei U; Varricchio C; Cazzaniga M; Lazzeroni M; Rotmensz N; Santillo B; Sideri M; Cassano E; Belloni C; Muraca M; Segnan N; Masullo P; Costa A; Monti N; Vella A; Bisanti L; D'Aiuto G; Veronesi U;
Ann Oncol; 2013 Nov; 24(11):2753-60. PubMed ID: 23864098
[TBL] [Abstract][Full Text] [Related]
13. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
16. Optimizing Expectations About Endocrine Treatment for Breast Cancer: Results of the Randomized Controlled PSY-BREAST Trial.
Shedden-Mora MC; Pan Y; Heisig SR; von Blanckenburg P; Rief W; Witzel I; Albert US; Nestoriuc Y
Clin Psychol Eur; 2020 Mar; 2(1):e2695. PubMed ID: 36397978
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Egawa C; Hirokaga K; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Mitsunobu M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):262-269. PubMed ID: 26411314
[TBL] [Abstract][Full Text] [Related]
18. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy.
Cella D; Fallowfield LJ
Breast Cancer Res Treat; 2008 Jan; 107(2):167-80. PubMed ID: 17876703
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
20. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
